CytoDyn (CYDY) Proxy Filing summary

Executive summary

• Entered a Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville Advisors) for up to $30 million in common stock over 36 months, with no obligation to utilize the full amount and no minimum commitments or penalties.

• Shares will be sold at 98% of the lowest daily VWAP during a three-day pricing period, with the company able to set a minimum acceptable price per share for each advance.

• Proceeds are intended for working capital, general corporate purposes, and debt repayment.

• The agreement provides flexibility for additional financings or strategic partnerships and does not restrict operating activities.

• No warrants, derivatives, or other share classes are associated with the funding arrangement.

Voting matters and shareholder proposals

• The board of directors has approved the transactions contemplated by the agreement, and such approval remains in full force and effect as of the agreement date.

Board of directors and corporate governance

• The board’s approval is a condition precedent for each advance under the agreement.

• The company must provide true, correct, and complete copies of board resolutions to the investor.